Azenta, Inc.

Equities

AZTA

US1143401024

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
52.18 ^USD	+1.32%		+3.02%	-19.90%

Apr. 08	Transcript : Azenta, Inc. Presents at 23rd Annual Needham Virtual Healthcare Conference, Apr-08-2024 12:45 PM
Apr. 04	Evercore ISI Raises Azenta's Price Target to $60 From $64, Maintains In Line Rating	MT

Azenta to Participate in the Virtual KeyBanc Life Sciences & MedTech Investor Forum

March 12, 2024 at 08:01 am EDT

BURLINGTON, Mass., March 12, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in Virtual KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024, which includes a presentation beginning at 12:45 pm ET. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event.

About Azenta Life Sciences

Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey and B Medical Systems.

Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

INVESTOR CONTACTS:
Sara Silverman
Head of Investor Relations & Corporate Communications
ir@azenta.com

Sherry Dinsmore
sherry.dinsmore@azenta.com

Azenta logo (PRNewsfoto/Azenta)

View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-to-participate-in-the-virtual-keybanc-life-sciences--medtech-investor-forum-302086361.html

SOURCE Azenta

Latest news about Azenta, Inc.

Transcript : Azenta, Inc. Presents at 23rd Annual Needham Virtual Healthcare Conference, Apr-08-2024 12:45 PM	Apr. 08
Evercore ISI Raises Azenta's Price Target to $60 From $64, Maintains In Line Rating	Apr. 04	MT
Jefferies Initiates Coverage on Azenta With Hold Rating, $64 Price Target	Apr. 04	MT
Azenta Seeks Tuck-In M&A	Mar. 19	CI
Transcript : Azenta, Inc. Presents at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum, Mar-19-2024 12:45 PM	Mar. 19
Nvidia's dizzying rally spurs rush into AI-themed ETFs	Mar. 19	RE
Transcript : Azenta, Inc. - Analyst/Investor Day	Mar. 14
Needham Trims Price Target on Azenta to $75 From $76, Maintains Buy Rating	Feb. 08	MT
Azenta's Fiscal Q1 Non-GAAP Earnings, Revenue Decline	Feb. 08	MT
Transcript : Azenta, Inc., Q1 2024 Earnings Call, Feb 07, 2024	Feb. 07
Azenta, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 07	CI
Earnings Flash (AZTA) AZENTA Posts Q1 EPS $0.02, vs. Street Est of $-0.03	Feb. 07	MT
Earnings Flash (AZTA) AZENTA Reports Q1 Revenue $154.3M, vs. Street Est of $151.2M	Feb. 07	MT
Azenta, Inc. Announces the Launch of the BioArc Ultra	Feb. 02	CI
Azenta, Inc. Announces Election of Directors	Feb. 01	CI
B. Riley Adjusts Azenta's Price Target to $79 From $61 Ahead of Fiscal Q1 Results Announcement, Keeps Buy Rating	Feb. 01	MT
Needham Adjusts Azenta's Price Target to $76 From $68, Keeps Buy Rating	Jan. 18	MT
Azenta, Inc. Provides Earnings Guidance for the Fiscal Year 2024	Jan. 18	CI
Transcript : Azenta, Inc. Presents at 26th Annual Needham Growth Virtual Conference, Jan-18-2024 10:15 AM	Jan. 18
Ellen M. Zane Decides Not to Stand for Election to the Board of Directors of Azenta, Inc	Jan. 17	CI
Transcript : Azenta, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 07:30 AM	Jan. 11
Tranche Update on Azenta, Inc.'s Equity Buyback Plan announced on November 14, 2022.	Jan. 10	CI
Transcript : Azenta, Inc. Presents at Stephens Annual Investment Conference \| NASH 2023, Nov-16-2023 11:00 AM	Nov. 16
Sector Update: Health Care Stocks Higher Late Afternoon	Nov. 14	MT
Sector Update: Health Care Stocks Advancing in Afternoon Trading	Nov. 14	MT

Chart Azenta, Inc.

Duration

Period

More charts

Company Profile

Azenta, Inc. is a provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Companyâs segments include Sample Management Solutions, Multiomics and B Medical Systems. The Sample Management Solutions segment offers end-to-end sample management products and services, including sample and repository services and core products (automated stores, cryogenic systems, automated sample tube, and consumables and instruments). The Multiomics segment provides genomic and other sample analysis services, including gene sequencing and gene synthesis. B Medical Systems segment is focused on the manufacturing and distribution of temperature-controlled storage and transportation solutions in international markets to governments, health institutions, and non-government organizations. It provides products and services through its brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems.

Sector

Biotechnology & Medical Research

Calendar

2024-04-30 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Azenta, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

52.18 USD

Average target price

66.8 USD

Spread / Average Target

+28.02%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AZENTA, INC.	-19.90%	2.91B
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research